PDCD1 and non-small cell lung carcinoma: In recent years, immune checkpoint inhibitors (ICIs), including anti-programmed cell death 1 (PD-1) or anti-programmed cell death ligand 1 (PD-L1) therapies, have revolutionized the treatment modalities of advanced non-small cell lung cancer (aNSCLC) (1–5).